cyclopropyl(4-fluorophenyl)methanamine | 705-14-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cyclopropyl(4-fluorophenyl)methanamine
• 英文别名: cyclopropyl-(4-fluorophenyl)methanamine
• CAS: 705-14-6
• 化学式: C₁₀H₁₂FN
• mdl: MFCD05191953
• 分子量: 165.21
• InChiKey: DMSWDNXXNCUYLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  cyclopropyl(4-fluorophenyl)methanamine 在 2-氯-1,3-二甲基氯化咪唑啉 、 三乙胺 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 28.0h， 生成 N-[cyclopropyl-(4-fluorophenyl)methyl]-N'-(2,2,2-trifluoro-1,1-dimethylethyl)methanediimine
  参考文献：
  名称：

  [EN] PESTICIDAL COMPOUNDS AND THEIR USES
  [FR] COMPOSÉS PESTICIDES ET LEURS UTILISATIONS

  摘要：

  本发明涉及特定的胍基化合物的环状衍生物及其在保护植物、控制蚊虫以及含有该胍基化合物环状衍生物的向量控制管理方法或控制溶液中的应用，具体而言，该发明涉及一种基质，一种包含胍基化合物环状衍生物的组合物，用于控制蚊虫。

  公开号：

  WO2017093409A1
• 作为产物：
  描述：

  4-氟苯基环丙基甲酮 在 palladium on activated charcoal 、 盐酸羟胺 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 cyclopropyl(4-fluorophenyl)methanamine
  参考文献：
  名称：

  [EN] METALLOENZYME INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES

  摘要：

  提供具有HDAC6调节活性的化合物，以及通过HDAC6介导的治疗疾病、疾病或症状的方法。

  公开号：

  WO2018165520A1

文献信息

• [EN] AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS D'AMINE AGISSANT COMME BLOQUEURS DU CANAL POTASSIUM
  申请人：BIONOMICS LTD

  公开号：WO2012155199A1

  公开（公告）日：2012-11-22

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及一种在细胞中调节钾通道活性的化合物，特别是发现在T细胞中的Kv1.3通道的活性。该发明还涉及利用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的药物组合物以及其制备方法。
• Cinnamide compound
  申请人：Kimura Teiji

  公开号：US20060004013A1

  公开（公告）日：2006-01-05

  The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.

  本发明涉及一种由式（I）表示的化合物：（其中Ar1代表可以被1到3个取代基取代的咪唑基团；Ar2代表可以被1到3个取代基取代的吡啶基团、嘧啶基团或苯基；X1代表（1）-C≡C-或（2）可以被取代的双键等；R1和R2代表，例如，可以被取代的C1-6烷基或C3-8环烷基等）或其药理学上可接受的盐，并且用作药物剂。本发明的目的是寻找一种治疗或预防由Aβ引起的疾病的药剂。根据本发明，可以提供治疗或预防由Aβ引起的疾病的药剂。
• [EN] BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES<br/>[FR] INHIBITEURS À LARGE SPECTRE DE FILOVIRUS
  申请人：MICROBIOTIX INC

  公开号：WO2018106667A1

  公开（公告）日：2018-06-14

  The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C 1 (NPCl) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

  本发明涉及开发用于治疗和/或预防人类和其他哺乳动物的Filovirus感染的治疗和预防剂。揭示了一类新的小分子，它抑制了自然加工（即蛋白酶水解）的Filovirus糖蛋白（GPCL）与其宿主受体Niemann-Pick C1（NPC1）蛋白的相互作用，从而阻止Filovirus感染宿主细胞。还揭示了在治疗/预防Filovirus感染中使用小分子抑制剂的方法。
• [EN] PROCESS FOR THE PREPARATION OF A DIASTEREOMERICALLY ENRICHED COMPOUND<br/>[FR] PROCEDE POUR LA PREPARATION D'UN COMPOSE ENRICHI EN DIASTEREOMERE
  申请人：DSM IP ASSETS BV

  公开号：WO2006008171A1

  公开（公告）日：2006-01-26

  The present invention relates to a process for the preparation of a diastereomerically enriched compound, wherein a first compound according to formula (I), is contacted with a second compound according to formula (II), to form a third compound according to formula (III), whereby the compound according to formula (III) is subsequently reduced and thereby converted into a compound according to formula (IV), in which formulas: R1= a cycloalkylgroup whereby R1 # R2, R2= a substituted or unsubstituted: (cyclo)alkyl group, (cyclo)alkenylgroup, aryl group, cyclic or acyclic heteroalkylgroup or heteroarylgroup, R3= an alkyl group, R4= a substituted or unsubstituted: phenyl- or naphthyl-group, *= a chiral center. The invention furthermore relates to a diastereomerically enriched compound according to formula (IV) and its use in the preparation of pharmaceutical and agrochemically active compounds. The invention further relates to a process for the preparation of enantiomerically enriched compounds of formula (V), through hydrogenolysis of diastereomerically enriched compounds of formula (IV), wherein R1 and R2 have the meanings given above.

  本发明涉及一种制备对映异构体富集化合物的过程，其中将式（I）的第一化合物与式（II）的第二化合物接触，形成式（III）的第三化合物，随后将式（III）的化合物还原，从而转化为式（IV）的化合物，其中式中：R1 = 环烷基，其中R1 ≠ R2，R2 = 取代或未取代的：（环）烷基，（环）烯基基团，芳基基团，环状或非环状杂基基团或杂环基团，R3 = 烷基，R4 = 取代或未取代的苯基或萘基，* = 手性中心。此外，本发明还涉及一种对映异构体富集化合物，其符合式（IV），以及其在制备制药和农业化学活性化合物中的应用。本发明还涉及一种制备式（V）的对映异构体富集化合物的过程，通过对式（IV）的对映异构体进行氢解，其中R1和R2具有上述含义。
• Mutations in the Pseudomonas aeruginosa Needle Protein Gene <i>pscF</i> Confer Resistance to Phenoxyacetamide Inhibitors of the Type III Secretion System
  作者：Nicholas O. Bowlin、John D. Williams、Claire A. Knoten、Matthew C. Torhan、Tommy F. Tashjian、Bing Li、Daniel Aiello、Joan Mecsas、Alan R. Hauser、Norton P. Peet、Terry L. Bowlin、Donald T. Moir

  DOI：10.1128/aac.02795-13

  日期：2014.4

  The type III secretion system (T3SS) is a clinically important virulence mechanism in Pseudomonas aeruginosa that secretes and translocates effector toxins into host cells, impeding the host's rapid innate immune response to infection. Inhibitors of T3SS may be useful as prophylactic or adjunctive therapeutic agents to augment the activity of antibiotics in P. aeruginosa infections, such as pneumonia and bacteremia. One such inhibitor, the phenoxyacetamide MBX 1641, exhibits very responsive structure-activity relationships, including striking stereoselectivity, in its inhibition of P. aeruginosa T3SS. These features suggest interaction with a specific, but unknown, protein target. Here, we identify the apparent molecular target by isolating inhibitor-resistant mutants and mapping the mutation sites by deep sequencing. Selection and sequencing of four independent mutants resistant to the phenoxyacetamide inhibitor MBX 2359 identified the T3SS gene pscF , encoding the needle apparatus, as the only locus of mutations common to all four strains. Transfer of the wild-type and mutated alleles of pscF , together with its chaperone and cochaperone genes pscE and pscG , to a Δ pscF P. aeruginosa strain demonstrated that each of the single-codon mutations in pscF is necessary and sufficient to provide secretion and translocation that is resistant to a variety of phenoxyacetamide inhibitor analogs but not to T3SS inhibitors with different chemical scaffolds. These results implicate the PscF needle protein as an apparent new molecular target for T3SS inhibitor discovery and suggest that three other chemically distinct T3SS inhibitors interact with one or more different targets or a different region of PscF.

  摘要 III型分泌系统（T3SS）是铜绿假单胞菌中一种临床上重要的毒力机制。 铜绿假单胞菌 Ⅲ型分泌系统（T3SS）是铜绿假单胞菌的一种重要临床毒力机制，它能将效应毒素分泌并转运到宿主细胞中，从而阻碍宿主对感染做出快速的先天免疫反应。T3SS 抑制剂可作为预防或辅助治疗药物，增强抗生素在铜绿假单胞菌感染中的活性。 铜绿假单胞菌 感染（如肺炎和菌血症）的抗生素活性。其中一种抑制剂是苯氧乙酰胺 MBX 1641，它对铜绿假单胞菌的抑制表现出非常灵敏的结构-活性关系，包括显著的立体选择性。 铜绿假单胞菌 T3SS。这些特征表明它与一个特定但未知的蛋白质靶点相互作用。在这里，我们通过分离抑制剂抗性突变体并通过深度测序绘制突变位点图，确定了明显的分子靶标。对四个对苯氧乙酰胺抑制剂 MBX 2359 具有抗性的独立突变体进行筛选和测序，确定了 T3SS 基因 pscF 是所有四个菌株唯一共同的突变位点。将野生型和突变等位基因的 的野生型和突变等位基因 及其伴侣蛋白和辅助伴侣蛋白基因 pscE 和 基因 转变为 Δ pscF 铜绿微囊藻 菌株中的每个单密码子突变都证明了 单密码子突变 中的每个单密码子突变对提供分泌和转运是必要且足够的，这些分泌和转运对多种苯氧乙酰胺抑制剂类似物具有抗性，但对具有不同化学支架的 T3SS 抑制剂没有抗性。这些结果表明，PscF 针蛋白显然是发现 T3SS 抑制剂的一个新分子靶点，并表明其他三种化学性质不同的 T3SS 抑制剂与 PscF 的一个或多个不同靶点或不同区域相互作用。